Japanese journal of clinical oncology最新文献

{"title":"Survival benchmarking of talazoparib plus enzalutamide in homologous recombination repair-deficient metastatic castration-resistant prostate cancer: a reconstructed individual patient data analysis.","authors":"Hiroki Tanaka, Hiroshi Fukushima, Shigehiro Tsukahara, Masaki Shiota, Soichiro Yoshida, Yasuhisa Fujii","doi":"10.1093/jjco/hyag152","DOIUrl":"https://doi.org/10.1093/jjco/hyag152","url":null,"abstract":"<p><p>Homologous recombination repair (HRR) alterations define a heterogeneous subgroup of metastatic castration-resistant prostate cancer. TALAPRO-2 established randomized benefit of talazoparib plus enzalutamide within HRR-deficient disease, but it did not determine whether treated HRR-deficient patients remain prognostically disadvantaged relative to biomarker-defined enzalutamide-alone reference groups. We performed exploratory trial-internal benchmarking using reconstructed individual patient data from published TALAPRO-2 Kaplan-Meier curves, with different endpoint-specific reference groups for radiographic progression-free survival (rPFS) and overall survival (OS). With enzalutamide alone, HRR-deficient disease had shorter rPFS than HRR-non-deficient disease (16.4 vs 22.3 months; HR 1.42, 95% CI 1.00-2.00) and shorter OS than disease with no HRR alteration detected (30.9 vs 37.7 months; HR 1.23, 95% CI 0.89-1.71). With talazoparib plus enzalutamide, corresponding medians were 27.9 and 45.8 months; cross-benchmark HRs were 0.73 (95% CI 0.50-1.07) and 0.66 (95% CI 0.46-0.96). These non-randomized comparisons are descriptive and do not establish equivalence, superiority, or prognostic normalization.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myeloma.","authors":"Kenshi Suzuki, Hiroshi Kosugi, Toshiro Ito, Yasushi Takamatsu, Peter M Voorhees, S Vincent Rajkumar, Miku Ito, Chika Sakai, Marimo Takahashi, Tomohiko Nakatogawa, Robyn Dennis, Robin Carson, Meletios A Dimopoulos","doi":"10.1093/jjco/hyag146","DOIUrl":"https://doi.org/10.1093/jjco/hyag146","url":null,"abstract":"<p><strong>Background: </strong>In the global phase 3 AQUILA trial, daratumumab monotherapy was associated with a significantly lower risk of progression to active multiple myeloma or death than active monitoring in patients with high-risk smoldering multiple myeloma without unexpected safety concerns (NCT03301220).</p><p><strong>Methods: </strong>Here, we report a subgroup analysis of Japanese patients from the trial. Among the 28 Japanese patients, 15 and 13 patients received daratumumab and active monitoring, respectively.</p><p><strong>Results: </strong>At the median follow-up of 60.9 months, the median progression-free survival was 59.1 and 24.8 months, respectively, with a hazard ratio of 0.25 [95% confidence interval (CI): 0.10-0.65] favoring daratumumab treatment. The overall response rate was 86.7% and 7.7%, with an odds ratio of 78.0 (95% CI: 6.24-974.71). Overall survival data were immature. Grade ≥3 adverse events were observed in five patients (33.3%) treated with daratumumab, which did not lead to treatment discontinuation, and no new safety concerns were noted.</p><p><strong>Conclusions: </strong>In this small-scale exploratory post hoc Japanese subgroup analysis, the efficacy of daratumumab monotherapy was generally comparable to that demonstrated in the global trial population, and no data suggesting new safety concerns were identified. These findings may provide useful information for determining treatment options in Japanese patients with high-risk smoldering multiple myeloma. Trial registration number:  ClinicalTrials.gov number, NCT03301220.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical recurrence patterns in hepatocellular carcinoma: greater consistency with the seed-and-soil hypothesis than with the anatomical/mechanical model of dissemination.","authors":"Yoshinori Takeda, Hiroshi Imamura, Hirofumi Ichida, Atsushi Takahashi, Shoichi Irie, Ryuji Yoshioka, Yoshihiro Mise, Akio Saiura","doi":"10.1093/jjco/hyag150","DOIUrl":"https://doi.org/10.1093/jjco/hyag150","url":null,"abstract":"<p><strong>Background: </strong>Recurrences of hepatocellular carcinoma (HCC) characterized by multiple intrahepatic nodules, macrovascular invasion, or extrahepatic metastases are generally considered non-curative and critically determine postoperative prognosis. Although such recurrences are commonly regarded as metastatic events, whether their dissemination primarily follows vascular anatomy or reflects biological compatibility between tumor cells and organ microenvironments remains unclear. We therefore evaluated whether these recurrence patterns are consistent with predictions derived from the anatomical/mechanical hypothesis of tumor dissemination.</p><p><strong>Methods: </strong>We retrospectively analyzed 266 patients who underwent initial liver resection for HCC. We examined (i) associations between subtypes of vascular invasion and subsequent recurrence patterns, (ii) temporal relationships among recurrence types, (iii) hierarchical co-occurrence of these events, and (iv) differences in malignant potential across recurrence types using serum alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) levels.</p><p><strong>Results: </strong>Portal and hepatic venous invasions occurred largely independently and showed no anatomical specificity in relation to recurrence patterns. Each subtype of vascular invasion was similarly associated with all forms of non-curative recurrence without anatomical specificity. Intrahepatic recurrence did not consistently precede extrahepatic metastasis, and no hierarchical relationship was observed among recurrence types. In contrast, patients with extrahepatic metastases had significantly higher AFP and DCP levels than those with intrahepatic non-curative recurrence.</p><p><strong>Conclusions: </strong>The spatial, temporal, hierarchical, and biological patterns of non-curative recurrence in HCC are more consistent with biologically selective dissemination as conceptualized by the seed-and-soil hypothesis than with the anatomical/mechanical model of dissemination.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976812","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastasis-directed local therapy and strategic de-escalation of systemic therapy for oligometastatic esophageal squamous cell carcinoma.","authors":"Motoo Nomura, Ken Kato, Takashi Ogata, Mitsuro Kanda, Yoichi Hamai, Yasuhiro Tsubosa, Takako Yoshii, Mitsuhiro Furuta, Katsuyuki Sakanaka, Kazuaki Matsui, Satoru Matsuda, Takahiro Tsushima, Hiroya Takeuchi","doi":"10.1093/jjco/hyag153","DOIUrl":"https://doi.org/10.1093/jjco/hyag153","url":null,"abstract":"<p><p>The introduction of immune checkpoint inhibitors (ICIs) has transformed the treatment of advanced esophageal squamous cell carcinoma (ESCC), yet the optimal duration of systemic therapy remains unsolved. Pivotal phase III trials capped ICI administration at 24 months, a design choice supported only indirectly by evidence from other tumor types suggesting a biological plateau in the antitumor immune response, since direct ESCC-specific evidence is lacking. In practice, however, 'oncological inertia,' the indefinite continuation of ICI therapy without a predefined stopping rule or objective marker of safety, contributes to cumulative toxicity and financial burden. This review proposes a 'strategic de-escalation' framework as an exit strategy. This framework uses metastasis-directed local consolidation therapy (LCT), surgical metastasectomy or ablative/precision radiotherapy to oligometastatic foci. This approach achieves definitive control of residual disease and thereby recasts subsequent ICI as a finite-duration adjuvant course. This course is analogous to postoperative nivolumab after chemoradiotherapy. It is an alternative to open-ended maintenance. Immediate, circulating tumor DNA (ctDNA)-driven discontinuation without an adjuvant course is a plausible but currently unproven alternative. Direct ESCC evidence for this exit strategy remains limited, and randomized trials in esophagogastric adenocarcinoma (REGATTA, RENAISSANCE) caution that aggressive local intervention can worsen outcomes without rigorous patient selection. The oligometastatic esophageal squamous cell carcinoma project uses a modified Delphi method to standardize the definition of oligometastatic ESCC and identify appropriate candidates. CtDNA may eventually guide the timing of treatment interruption and rechallenge. We discuss the rationale, current limitations, and prospective validation needs for this strategy in the multidisciplinary management of ESCC.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148976815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors of docetaxel-induced peripheral edema in non-small cell lung cancer treatment: a multi-institutional cohort study.","authors":"Shinsuke Yamashita, Yoshitaka Saito, Shinya Tamaki, Daisuke Hirate, Karin Wakai, Itsuki Yonezawa, Honoka Hirasawa, Hitoshi Kashiwagi, Yuki Sato, Shungo Imai, Shunsuke Nashimoto, Jun Sakakibara-Konishi, Yasushi Shimizu, Ichiro Kinoshita, Ryo Takagi, Mitsuru Sugawara, Yoh Takekuma","doi":"10.1093/jjco/hyag091","DOIUrl":"10.1093/jjco/hyag091","url":null,"abstract":"<p><strong>Background: </strong>Peripheral edema is an adverse event associated with docetaxel (DTX). However, previous studies on DTX-induced peripheral edema have been limited to patients with breast cancer. Therefore, evaluation of symptoms in other cancer types is essential. We aimed to identify the factors associated with this symptom in patients with non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>This retrospective multicenter observational study evaluated 170 patients with NSCLC who received DTX between April 2014 and December 2024. The primary endpoint was factors associated with grade ≥ 2 DTX-induced peripheral edema during up to seven cycles. Additionally, we evaluated the factors for all-grade symptoms.</p><p><strong>Results: </strong>The incidences of grade ≥ 2 and all-grade DTX-induced peripheral edema were 13.5% and 30.0%. The median cumulative DTX dose at symptom onset was 144 (interquartile range, 60-254) mg/m2 for grade ≥ 2 DTX-induced peripheral edema and 120 (60-210) mg/m2 for all-grade symptoms. The Fine-Gray sub-distribution hazard models revealed that the co-administration of ramucirumab (RAM) was significantly associated with the incidence of DTX-induced peripheral edema (grade ≥ 2: sub-distribution hazard ratio [SDHR], 3.51; 95% confidence interval [CI], 1.34-9.24; P = 0.011) (all-grade: SDHR, 2.17; 95% CI, 1.20-3.92; P = 0.011). The Gray's test demonstrated that the cumulative incidence of DTX-induced peripheral edema was significantly higher in the DTX + RAM group than in the DTX monotherapy group (P = 0.003 and < 0.001 for grade ≥ 2 and all-grade symptoms, respectively).</p><p><strong>Conclusions: </strong>We revealed that co-administration of RAM is a risk factor for DTX-induced peripheral edema in patients with NSCLC.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1088-1096"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148591739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-standardized mortality-to-incidence ratio for lip and oral cavity cancer in the world.","authors":"Kayo Nakata, Hadrien Charvat","doi":"10.1093/jjco/hyag134","DOIUrl":"https://doi.org/10.1093/jjco/hyag134","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":"56 9","pages":"1156-1157"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical utility of tumour markers in skeletal metastasis of unknown primary at the initial visit.","authors":"Kensaku Yamaga, Keiichi Akahori, Mari Osaki, Hideki Nagashima","doi":"10.1093/jjco/hyag074","DOIUrl":"10.1093/jjco/hyag074","url":null,"abstract":"<p><strong>Background: </strong>Skeletal metastasis of unknown primary at the initial visit represents a clinically important subset of metastatic bone tumours, accounting for ~7.8%-21.7% of all skeletal metastases. This condition differs from cancer of unknown primary (CUP), in which the primary site remains unidentified after comprehensive evaluation. At this diagnostic entry point, before completion of a full work-up, early stratification is essential; however, the clinical utility of serum tumour markers at this stage remains unclear.</p><p><strong>Methods: </strong>We retrospectively reviewed 79 patients who presented with skeletal metastasis of unknown primary at the initial visit before diagnostic work-up between January 2010 and October 2023. Clinical characteristics, final primary diagnoses, types of tumour markers measured, positivity rates, and diagnostic performance were analysed.</p><p><strong>Results: </strong>Haematologic malignancies were the most frequent final diagnoses (40.5%), followed by lung (22.8%) and prostate cancer (10.1%). A total of 17 tumour markers were measured (mean, 6.3 per patient; range, 0-12). Prostate-specific antigen (PSA), immunoelectrophoresis (IEP), soluble interleukin-2 receptor (sIL-2R), and thyroglobulin (Tg) showed high sensitivity and specificity for prostate cancer, multiple myeloma, malignant lymphoma, and thyroid cancer, respectively. Carcinoembryonic antigen (CEA) and cytokeratin 19 (CK19, CYFRA 21-1), although not organ-specific, were frequently positive in carcinomas and served as indicators of epithelial malignancy.</p><p><strong>Conclusions: </strong>Serum tumour markers can assist early diagnostic stratification at the initial presentation of skeletal metastasis before primary-site identification. A selective testing strategy focusing on sIL-2R, IEP, CEA, and CK19, with PSA added in men and Tg when clinically indicated, may improve diagnostic efficiency and provide a basis for considering a bone-metastasis-oriented diagnostic approach.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1097-1102"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of multimodality therapy stratified by resection rate and molecular markers in children and adolescents with ependymoma: JCCG EPN23 protocol.","authors":"Rieko Taniguchi, Yoshiki Shiba, Fumiharu Ohka, Shoichi Deguchi, Aya Sato, Hideki Muramatsu, Takako Yoshioka, Junko Hirato, Koichi Ichimura, Kumiko Nozawa, Akira Gomi, Katsuya Maebayashi, Eisuke Inoue, Miho Kato, Kai Yamasaki, Yoshiki Arakawa, Toshihiro Kumabe, Ryuta Saito","doi":"10.1093/jjco/hyag083","DOIUrl":"10.1093/jjco/hyag083","url":null,"abstract":"<p><strong>Background: </strong>Ependymomas are rare pediatric brain tumors characterized by clinical and molecular heterogeneity. The JCCG EPN23 study is a nationwide prospective trial in Japan designed to evaluate outcomes of risk-adapted therapy stratified by tumor location, extent of resection, and molecular classification.</p><p><strong>Methods: </strong>Patients younger than 30 years with pathologically confirmed ependymoma are enrolled and assigned to one of three treatment strata. Stratum 1 evaluates whether omission of radiation therapy for patients with gross total resection of supratentorial or non-PFA infratentorial tumors. Stratum 2 administers radiation therapy followed by maintenance oral etoposide for patients with minimal residual tumors or PFA subtype. Stratum 3 provides neoadjuvant chemotherapy to facilitate total resection of residual tumors. Patients younger than 1 year and those with metastatic or extracranial disease are assigned to an observational cohort, in which no specific treatment is mandated by study protocol. Central surgical and pathological review, along with molecular and DNA methylation profiling, are conducted to improve diagnostic precision and prognostic stratification.</p><p><strong>Results: </strong>The study prospectively evaluates the feasibility and efficacy of radiation-sparing strategies in selected patient groups and other risk-adapted treatment approaches. Outcomes including survival, disease control, and treatment-related morbidity will be analyzed according to each risk group.</p><p><strong>Conclusions: </strong>JCCG EPN23 aims to optimize therapeutic strategies for pediatric ependymoma by integrating molecular classification with risk-adapted treatment. The results are expected to inform future treatment protocols and improve survival while minimizing long-term morbidity.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1133-1138"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of disease-specific late effects after proton beam therapy in pediatric solid and CNS tumor survivors: a single-institution survey in Japan.","authors":"Hiroko Fukushima, Sho Hosaka, Ryoko Suzuki, Yuni Yamaki, Masako Inaba, Kumie Nagatomo, Ai Muroi, Kouji Masumoto, Takashi Saito, Masashi Mizumoto, Hideyuki Sakurai, Hidetoshi Takada","doi":"10.1093/jjco/hyag081","DOIUrl":"10.1093/jjco/hyag081","url":null,"abstract":"<p><strong>Background: </strong>Proton beam therapy (PBT) has been increasingly adopted in pediatric oncology to reduce radiation-related toxicity; however, its long-term comorbidities remain incompletely understood. Because tumor types and treatment patterns often overlap across diagnostic groups, disease-specific evaluation may help clarify late effects following PBT.</p><p><strong>Methods: </strong>A mailed questionnaire survey was conducted between 2015 and 2021 among 304 pediatric cancer survivors who had received PBT at the University of Tsukuba Hospital between 1984 and 2020. Responses from 110 patients diagnosed before the age of 20 years and alive at the time of the survey were analyzed. A non-PBT cohort treated between 1976 and 2013 served as a comparison group.</p><p><strong>Results: </strong>The median follow-up duration was 6.3 years (range, 0.4-34.6). Thirty-six patients (33%) reported no comorbidities. Severe (grade ≥3) comorbidities occurred in 3 PBT patients (gait disturbance, renal failure requiring dialysis, and hemianopsia) and 1 non-PBT patient (secondary colorectal cancer that might have been avoided with PBT). Skeletal abnormality was the most frequent late effect, followed by hair abnormality, growth retardation, chronic skin disorders, endocrine dysfunction, dental abnormalities, and neurocognitive impairment. Skeletal abnormality was significantly associated with rhabdomyosarcoma and Ewing sarcoma family of tumors, whereas hormone replacement therapy was more common among patients with central nervous system germ cell tumors.</p><p><strong>Conclusions: </strong>This single-institution disease-specific analysis revealed distinct comorbidity patterns among childhood cancer survivors treated with PBT. Although severe late effects were rare, musculoskeletal and endocrine disorders were frequent, underscoring the need for diagnosis-tailored, long-term follow-up strategies.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1074-1079"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13556386/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147972686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Authors' reply to \"Reconsidering prostate cancer screening: limitations of net survival and the primacy of overall survival as an endpoint\".","authors":"Rina Tanaka, Michel P Coleman, Masashi Matsuzaka, Hiromi Sugiyama, Veronica Di Carlo, Tomohiro Matsuda, Claudia Allemani","doi":"10.1093/jjco/hyag076","DOIUrl":"10.1093/jjco/hyag076","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1154-1155"},"PeriodicalIF":2.5,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148277464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}